<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088137</url>
  </required_header>
  <id_info>
    <org_study_id>FSG-03-01</org_study_id>
    <nct_id>NCT03088137</nct_id>
  </id_info>
  <brief_title>Study to Compare Efficacy and Safety of Primapur and Gonal-f in Women for Assisted Reproductive Treatment</brief_title>
  <official_title>Multicentre Study to Compare Efficacy and Safety of Primapur and Gonal-f in Women for Assisted Reproductive Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVFarma LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BridgePharm LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IVFarma LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show equivalence with regard to the number of oocytes
      retrieved between follitropin alfa (pen-injectors) Primapur® and Gonal-f® in woman undergoing
      IVF/ICSI
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2017</start_date>
  <completion_date type="Anticipated">May 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of oocytes retrieved</measure>
    <time_frame>From date of randomization up to 18 days</time_frame>
    <description>The total number of retrieved oocytes at the day of ovum pick-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and size of follicles ≥ 16 mm</measure>
    <time_frame>From date of randomization up to 16 days</time_frame>
    <description>The number and size of follicles 16 mm or over in diameter at day of hCG administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of oocytes</measure>
    <time_frame>From date of randomization up to 18 days</time_frame>
    <description>Mature oocytes (MII stage of development)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilisation rate</measure>
    <time_frame>From date of randomization up to 19 days</time_frame>
    <description>Fertilisation rate (presence of two pronuclei:2PN)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with embryo transfer</measure>
    <time_frame>From date of randomization up to 25 days</time_frame>
    <description>Embryo transfer rate (Days 2-5 after ovum pick-up)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of follitropin alfa</measure>
    <time_frame>From date of randomization up to 16 days</time_frame>
    <description>Mean dose of follitropin alfa for ovarian hyperstimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of follitropin alfa treatment</measure>
    <time_frame>From date of randomization up to 16 days</time_frame>
    <description>Mean duration of ovarian hyperstimulation (at the day of hCG administration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with follitropin alfa dose correction</measure>
    <time_frame>From date of randomization up to 16 days</time_frame>
    <description>Mean number of dose adjustments (increment 25-50 IU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with cycle cancellation</measure>
    <time_frame>From date of randomization up to 16 days</time_frame>
    <description>Mean cancellation rate during ovarian hyperstimulation (at the day of hCG administration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of no-responders</measure>
    <time_frame>From date of randomization up to 8 days</time_frame>
    <description>Number of patients with no response to follitropin alfa treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy rate</measure>
    <time_frame>From date of randomization up to 42 days</time_frame>
    <description>Serum hCG more than 25 IU/l (days 12-17 after embryo transfer)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>From date of randomization up to 14 weeks</time_frame>
    <description>Presence of at least one intrauterine gestational sac</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>Primapur (Follitropin alfa)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gonal-f (Follitropin alfa)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follitropin alfa (Gonal-f)</intervention_name>
    <description>Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
    <arm_group_label>Gonal-f (Follitropin alfa)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follitropin alfa (Primapur)</intervention_name>
    <description>Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
    <arm_group_label>Primapur (Follitropin alfa)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infertility due to tubal factor and/or male factor

          -  Age between 20 and 35 years with regular menstrual cycles of 21-35 days

          -  First or second cycle in the present series of ART

          -  BMI ≥ 18 ≤ 30 kg/m2

          -  Basal FSH &lt; 10 IU/L (cycle day 2-5)

          -  E2 levels &lt; 50pg/mL (cycle day 2)

          -  AMH ≥ 1.0 ng/ml

          -  Antral follicle count (AFC) ≥ 4 to ≤ 15 follicles (both ovaries)

          -  Presence of both ovaries and normal uterine cavity

          -  Informed consent

        Exclusion Criteria:

          -  Presence of pregnancy

          -  Hypersensitivity to follitropin alfa

          -  Ovarian cysts

          -  History of ≥2 succeeding ART cycles (IVF and/or ICSI) before the study cycle

          -  Previous history of severe ovarian hyperstimulation syndrome

          -  Presence of polycystic ovaries (PCO)

          -  Presence of endometriosis and hydrosalpinx

          -  Presence of uterine disorders

          -  History of poor (&lt; 4 oocytes) or hyper (&gt; 25 oocytes) responses to FSH treatment at
             dose 150 IU and GnRH-antagonist protocol

          -  Premature ovarian failure

          -  Ectopic pregnancy (3 month before the study cycle)

          -  Presence of clinically significant systemic disease

          -  Presence of chronic cardiovascular, hepatic, renal or pulmonary disease

          -  Presence of endocrine disorder

          -  Neoplasia

          -  Male infertility without mobile spermatozoa in the ejaculate, that need MESA/TESE/TESA

          -  Smoking &gt; 10 cigarettes/day

          -  Narcomania, alcoholism

          -  Planned PGS/PGD
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Hospital Lapino</name>
      <address>
        <city>Moscow Oblast</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raisa Shalina, D.Sc.</last_name>
      <phone>+7 (495) 526-60-60</phone>
      <email>lpn.info@mcclinics.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AltraVita IVF clinic</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatyana Teterina, PhD</last_name>
      <phone>+7 (499) 969-81-58</phone>
      <email>info@altravita-ivf.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Perinatal Medical Center</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lali Sichinava, D.Sc.</last_name>
      <phone>+7 (495) 331-85-10</phone>
      <email>info@mospmc.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>in vitro fertilization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

